Collegium Pharmaceutical Stock News

Collegium Pharmaceutical, Inc. (COLL) CEO Joe Ciaffoni on Q4 2021 Results - Earnings Call Transcript

Collegium Pharmaceutical (NASDAQ:COLL) is scheduled to announce Q4 earnings results on Thursday, February 24th, after market close.The consensus EPS Estimate is $1.04 (+420.0% Y/Y) and…

Collegium Pharmaceutical has seen a decent 2021, but starts 2022 with a big and interesting deal. Investors are highly attracted to diversification and in anticipation of huge synergies.

Collegium Pharmaceutical Inc. (NASDAQ:COLL) shares, rose in value on Friday, 02/18/22, with the stock price down by -1.09% to the previous days close as strong demand from buyers drove the stock to $21.75. Actively observing the price movement in the last trading, the stock closed the session at $21.99, falling within a range of $21.21 Analysts Predict An Collegium Pharmaceutical Inc. (NASDAQ: COLL) Spike? Read More »

NEW YORK, Feb. 16, 2022 (GLOBE NEWSWIRE) -- Halper Sadeh LLP, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: BioDelivery Sciences International, Inc. (NASDAQ: BDSI )''s sale to Collegium Pharmaceutical, Inc. for $5.60 per share. If you are a BioDelivery shareholder, click here to learn more about your rights and options . Zurn Water Solutions Corporation (NYSE: ZWS )''s merger with Elkay Manufacturing Company. If you are a Zurn Water shareholder, Full story available on Benzinga.com

Collegium Pharmaceutical, Inc. (NASDAQ: COLL) and BioDelivery Sciences International Inc. (NASDAQ: BDSI) have announced a definitive agreement where Collegium will acquire BDSI for USD 5.60 per share in cash. BDSI holds a portfolio of pain and neurology products that focus on serious and debilitating conditions. We are excited to announce this acquisition, which represents a major step forward in our mission to build a leading, diversified specialty pharmaceutical company committed to improving the lives of people suffering from serious medical conditions, said Joe Ciaffoni, President and Chief Executive Officer of Collegium. The BDSI portfolio expands and enhances Collegiums differentiated pain offerings and establishes a foothold in neurology, a strategic market adjacency. Importantly, we expect this acquisition will be immediately and highly accretive by expanding our revenue scale and generating significant synergies.

BioDelivery Sciences International BDSI +51% Collegium Pharmaceutical to acquire BioDelivery Sciences for $5.60/share in all cash deal.Cornerstone Building Brands (CNR) +22% CD&R…

Collegium Pharmaceutical Inc (NASDAQ: COLL ) will acquire BioDelivery Sciences International Inc (NASDAQ: BDSI ) at $5.60 per share in an all-cash transaction, corresponding to an equity value of approximately $604 million . The consideration represents a 54% premium to BDSI common stock''s closing price of $3.64 on Full story available on Benzinga.com

Shares of BioDelivery Sciences International Inc. blasted 51.7% higher to pace all premarket gainers Monday, after the specialty pharmaceutical company with a portfolio of pain and neurology products agreed to be acquired by Collegium Pharmaceutical Inc. in a deal valued at about $604 million. Collegium''s stock was still inactive ahead of the open. Under terms of the deal, Collegium will pay $5.60 in cash for each BioDelivery share outstanding, which represents a 53.8% premium to Friday''s closing price of $3.64. The deal is expected to close in the first quarter of 2022. BioDelivery''s stock, which is on track to open at a two-year high, has rallied 12.4% over the past three months and Collegium shares have dropped 9.7%, while the S&P 500 has lost 5.6%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

BioDelivery Sciences International (BDSI) soared 51.1% in premarket amid merger agreement with Collegium Pharmaceutical (COLL).Under the deal, Collegium Pharmaceutical to purchase

STOUGHTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday, February 24, 2022, at 4:30 p.m. Eastern Time. The Company will discuss its fourth quarter and full-year 2021 financial results and provide a corporate update.

STOUGHTON, Mass., Feb. 10, 2022 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced that the Company will host a conference call and live audio webcast on Thursday, Febru

Wall Street brokerages expect Collegium Pharmaceutical, Inc. (NASDAQ:COLL) to announce $81.59 million in sales for the current fiscal quarter, according to Zacks Investment Research. Four analysts have provided estimates for Collegium Pharmaceuticals earnings, with the highest sales estimate coming in at $82.40 million and the lowest estimate coming in at $80.46 million. Collegium Pharmaceutical posted []